Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (DE:ETF)
BERLIN:ETF
Holding DE:ETF?
Track your performance easily
ETF Stock Chart & Stats
Day’s Range€0.04 - €0.05
52-Week Range― - ―
Previous Close€0.04
Volume0.00
Average Volume (3M)N/A
Market Cap
$97.09M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 14, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Elite Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors
ETF FAQ
What was Elite Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Elite Pharmaceuticals’s market cap?
Currently, no data Available
When is Elite Pharmaceuticals’s upcoming earnings report date?
Elite Pharmaceuticals’s upcoming earnings report date is Nov 14, 2023 which is 360 days ago.
How were Elite Pharmaceuticals’s earnings last quarter?
Elite Pharmaceuticals released its earnings results on Aug 14, 2023. The company reported <€0.001 earnings per share for the quarter, beating the consensus estimate of N/A by <€0.001.
Is Elite Pharmaceuticals overvalued?
According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued.
Does Elite Pharmaceuticals pay dividends?
Elite Pharmaceuticals does not currently pay dividends.
What is Elite Pharmaceuticals’s EPS estimate?
Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elite Pharmaceuticals have?
Currently, no data Available
What happened to Elite Pharmaceuticals’s price movement after its last earnings report?
Elite Pharmaceuticals reported an EPS of <€0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elite Pharmaceuticals?
Among the largest hedge funds holding Elite Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Elite Pharmaceuticals’s shares valued at N/A.
---
Elite Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
359.37%
12-Months-Change
Fundamentals
Return on Equity
15.80%
Trailing 12-Months
Asset Growth
-3.34%
Trailing 12-Months
Company Description
Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment comprises the branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.
---
Technical Analysis
Acer Therapeutics
―
Acelrx
―
Apellis Pharmaceuticals
―
Avadel Pharmaceuticals
―
Elite Pharmaceuticals
―
---